Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDIE: Tislelizumab in Early-Stage Unfavorable cHL
NCT04837859Phase 2Recruiting
- Sponsor
- University of Cologne
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Started May 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04837859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04837859.